Dr. Mark Andrew Walshauser, MD

Dr. Walshauser practices at Cancer Care Specialists of Central Illinois, S.C. in Decatur, Illinois.

Dr. Walshauser's NPI, 1306020664, was assigned on December 21, 2007. Dr. Walshauser holds Illinois license 036128331.

Dr. Walshauser's primary practice is Cancer Care Specialists of Central Illinois, S.C., at 210 W McKinley Ave, Decatur, IL 62526 in Macon County. The practice phone is (217) 876-6600.

Dr. Walshauser's primary practice is Cancer Care Specialists of Central Illinois, S.C. in Decatur, Illinois. Dr. Walshauser is also affiliated with HSHS St. John's Hospital. The medical group on file is Cancer Care Specialists of IL. Dmand AI also links Dr. Walshauser to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Walshauser practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Walshauser's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Walshauser's licenses on file in 2 states: Illinois and Missouri.

CMS data shows 100,535 Medicare services from Dr. Walshauser across 64 procedure codes in 2024, for 524 Medicare patients. Medicare paid $528,613 for them.

CMS counts 524 Medicare patients who saw Dr. Walshauser in 2024. The largest group is 65 to 74, with 221 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Walshauser's median patient age at 71, with 60% women.

In 2024, Dr. Walshauser wrote 1,534 Medicare Part D claims for 283 patients. 80% of them were for generic drugs. CMS names the drug for 1,288 of them, across 38 drugs with 11 or more claims each, at $3,366,239 in total drug cost. In 2023, CMS named 1,115 claims across 35 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Walshauser for performance year 2024, reported as part of a group. Dr. Walshauser accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 6 papers to Dr. Walshauser, published from 2010 to 2025. 2019 was the busiest year, with 2. Dr. Walshauser's most frequent co-authors are Michael Richard Grunwald, MD, David John Kuter, MD and Ruben Anthony Mesa, MD.

CMS Open Payments shows 1,243 general payments to Dr. Walshauser from 72 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 59% of the total. Incyte Corporation paid the most, $5,171.